EPX-100 (Clemizole HCl) ( DrugBank: Clemizole )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 140 | Dorabe syndrome | 1 |
140. Dorabe syndrome
Clinical trials : 104 / Drugs : 61 - (DrugBank : 14) / Drug target genes : 48 - Drug target pathways : 63
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04462770 (ClinicalTrials.gov) | September 15, 2020 | 6/7/2020 | EPX-100 (Clemizole Hydrochloride) as Add-on Therapy to Control Convulsive Seizures in Patients With Dravet Syndrome | A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Patients With Dravet Syndrome | Dravet Syndrome | Drug: EPX-100 (Clemizole HCl);Drug: Placebo | Epygenix | NULL | Recruiting | 2 Years | 80 Years | All | 60 | Phase 2 | United States;Canada |